Biomedical Engineering Reference
In-Depth Information
83. Etienne-Grimaldi MC, Pereira S, Magné N,
Analysis of the
dinucleotide repeat polymorphism in the epidermal growth factor
receptor (EGFR) gene in head and neck cancer patients.
et al.
Ann Oncol
16,
934-941 (2005).
84. Nie Q, Wang Z, Zhang GC,
et al.
The epidermal growth factor receptor
intron1 (CA)
microsatellite polymorphism is a potential predictor of
treatment outcome in patients with advanced lung cancer treated with
Gefitinib.
n
570, 175-181 (2007).
85. Liu G, Gurubhagavatula S, Zhou W,
Eur J Pharmacol
Epidermal growth factor
receptor polymorphisms and clinical outcomes in non-small-cell lung
cancer patients treated with gefitinib.
et al.
Pharmacogenomics
8, 129-138
(2008).
86. Huang C-L, Yang C-H, Yeh K-H,
intron 1 dinucleotide repeat
polymorphism is associated with the occurrence of skin rash with
gefitinib treatment.
et al.
EGFR
Lung Cancer
64, 346-351 (2009).
87. Liu G, Cheng D, Le Maitre A,
EGFR and ABCG2 polymorphisms
as prognostic and predictive markers in the NCIC CTG BR.21 trial of
single-agent erlotinib in advanced non-small cell lung cancer (NSCLC).
[Abstract 7538] JCO 28s (2010).
88. Liu W, Innocenti F, Wu MH,
et al.
A functional common polymorphism
in a Sp1 recognition site of the epidermal growth factor receptor gene
promoter.
et al.
65, 46-53 (2005).
89. Gregorc V, Hidalgo M, Spreafico A,
Cancer Res
Germline polymorphisms in
EGFR and survival in patients with lung cancer receiving gefitinib.
et al.
Clin
83, 477-484 (2008).
90. Cusatis G, Gregorc V, Li J,
Pharmacol Ther
et al.
Pharmacogenetics of ABCG2 and adverse
98, 1739-1742 (2006).
91. Hodgson DR, Wellings R, Orr MCM,
reactions to gefitinib.
JNCI
et al.
Circulating tumor-derived
predictive biomarkers in oncology.
Drug Discov Today
15, 98-101
(2010).
92. Maheswaran S Haber DA. Circulating tumor cells: a window into cancer
biology and metastasis.
Curr Opin Genet Dev
20, 96-99 (2010).
93. Allard WJ, Matera J, Miller MC,
Tumor cells circulate in the
peripheral blood of all major carcinomas but not in healthy subjects or
patients with nonmalignant diseases.
et al.
Clin Cancer Res
10, 6897-6904
(2004).
94. Nagrath S, Sequist LV, Maheswaran S,
Isolation of rare circulating
tumour cells in cancer patients by microchip technology.
et al.
Nature
450,
1235-1239 (2007).
